Delivery Order SPE2DB24D2100-SPE2DB25FBGPS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors with a ceiling value of $4,379.74 and ultimate completion date of September 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open competition. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors in 0.5 mL quantities, with a ceiling value of $1,906.45. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and is scheduled for completion by August 28, 2025. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $34,076.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injectors. This non-competitive, non-set-aside delivery order is scheduled for ultimate completion on July 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors, with a contract ceiling value of $24,832.86 and an ultimate completion date of August 18, 2025. This is a firm fixed-price, competitive delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors on August 18, 2025, with a ceiling value of $3,291.68 and ultimate completion date of August 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pen injections with a ceiling value of $1,525.20. This competitive award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contractor will perform at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections valued at $11,887.80. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor and critical federal...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGPSDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This firm fixed-price delivery order, valued at $35,744.56, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and medical devices to support military healthcare programs and other federal medical procurement needs, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal contracts demonstrates its established capability to meet competitive procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.7k | 9/23/25 |